MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

Resistance to endocrine therapy in estrogen receptor-positive (ER(+)) breast cancer is a major clinical problem with poorly understood mechanisms. There is an unmet need for prognostic and predictive biomarkers to allow appropriate therapeutic targeting. We evaluated the mechanism by which minichrom...

Descripción completa

Detalles Bibliográficos
Autores principales: Løkkegaard, Sanne, Elias, Daniel, Alves, Carla L., Bennetzen, Martin V., Lænkholm, Anne-Vibeke, Bak, Martin, Gjerstorff, Morten F., Johansen, Lene E., Vever, Henriette, Bjerre, Christina, Kirkegaard, Tove, Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle, Lindström, Linda S., Esserman, Laura J., Lykkesfeldt, Anne E., Andersen, Jens S., Leth-Larsen, Rikke, Ditzel, Henrik J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782683/
https://www.ncbi.nlm.nih.gov/pubmed/33398005
http://dx.doi.org/10.1038/s41523-020-00210-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782683/
https://www.ncbi.nlm.nih.gov/pubmed/33398005
http://dx.doi.org/10.1038/s41523-020-00210-8

Ejemplares similares